Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.

Bibliographic Details
Title:	Calibration and validation of modeled 5-year survival predictions among people with cystic fibrosis treated with the cystic fibrosis transmembrane conductance regulator modulator ivacaftor using United States registry data.
Authors:	McGarry LJ; Vertex Pharmaceuticals Incorporated, Boston, MA, United States of America., Bhaiwala Z; Vertex Pharmaceuticals Incorporated, Boston, MA, United States of America., Lopez A; Vertex Pharmaceuticals Incorporated, Boston, MA, United States of America., Chandler C; Evidera, Waltham, MA, United States of America., Pelligra CG; Evidera, Bogotá, Colombia., Rubin JL; Vertex Pharmaceuticals Incorporated, Boston, MA, United States of America., Liou TG; Adult CF Center, University of Utah, Salt Lake City, UT, United States of America.
Source:	PloS one [PLoS One] 2023 Apr 12; Vol. 18 (4), pp. e0283479. Date of Electronic Publication: 2023 Apr 12 (Print Publication: 2023).
Publication Type:	Journal Article; Research Support, Non-U.S. Gov't
Journal Info:	Publisher: Public Library of Science Country of Publication: United States NLM ID: 101285081 Publication Model: eCollection Cited Medium: Internet ISSN: 1932-6203 (Electronic) Linking ISSN: 19326203 NLM ISO Abbreviation: PLoS One Subsets: MEDLINE
Database:	MEDLINE Complete
Full text is not displayed to guests.	Login for full access.

Description
ISSN:	1932-6203
DOI:	10.1371/journal.pone.0283479